Thank you for all your tireless efforts Mozz. If PAR had as many...

Thank you for all your tireless efforts Mozz. If PAR had as many HC followers as some of the other stocks on here, you no doubt would be a top five most liked poster most days. A lightbulb doesn't convey the thanks a lot of us have for your efforts to educate and share your detailed research.

The implications for heart disease could be massive. The biggest killer globally.

Stenosis, or the narrowing of the heart valves, is a relatively common condition. It can occur in any of the four heart valves but is most often seen in the aortic and mitral valves. Aortic stenosis, in particular, is one of the most common and most serious valve disease problems. Aortic stenosis is typically a condition that progresses with age. Moderate to severe aortic stenosis can lead to significant symptoms and complications, including heart failure, and can be life-threatening.

Aortic stenosis is present in up to 9% of Americans aged 65 and older. Once symptoms appear, the prognosis without treatment is poor. Among symptomatic patients with severe aortic stenosis, if left untreated, 50% die within 2 years and 80% within 5 years.

Aortic stenosis is often treatable with aortic valve replacement, which can significantly improve prognosis.
Imagine using iPPS to remove the need for aortic valve replacements, or being used as a prophylactic to avoid aortic stenosis in the first place.

The UN projects that the number of older persons (aged 65 years or over) will more than double to 1.5 billion in 2050.
If you extrapolate that, you are talking 135m people in the world with aortic stenosis by 2050.

Then there are the 10-15% of old persons (aged 65 years or over) that have osteoarthritis.

The Centers for Disease Control and Prevention (CDC) has reported that approximately 20.4% (50 million) adults in the United States have chronic pain, with 8% of adults (19.6 million) experiencing high-impact chronic pain.

That's approximately 15% of the entire population. Drop that to 5% globally and you are still talking 400m people that iPPS could help.

The markets for iPPS are so massive, that I truly think people are going to be shocked at how far this company goes.

As Mozz pointed out, I'm sure there were people skeptical of CSL when it first started out. There no doubt where people saying, if it's going to be so big, it will just get bought out, or then why is it only worth 76c.

Twiggy Forrest took a long time to sell people on the potential of FMG.
The science and market opportunities for PAR and iPPS are far bigger than most can imagine.

The other indications that iPPS are hopefully going to help are endless.
Inflammation plays a major role in all neurodegenerative diseases. There are a lot of different diseases.
MPS I/VI , RA, RRV, OA... are all just the beginning of iPPS' potential in my opinion.